جست‌وجوی استاد و پژوهشگر

Syed Hani Hassan Abidiمشاهده پروفایل

دانشیار

• Virology
• Immunology
• Viral Oncology
• +۷ مورد دیگر

Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .

Daniel Finleyمشاهده پروفایل

استاد

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +۷ مورد دیگر

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

Vadim Cherezovمشاهده پروفایل

استاد

• Membrane Protein Structure and Function
• G Protein-Coupled Receptors (GPCRs)
• Lipid-Protein Interactions
• +۳ مورد دیگر

Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.

Brian Hieمشاهده پروفایل

استادیار

• Machine Learning
• Computational Biology
• Protein Engineering
• +۶ مورد دیگر

Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .

Wei-Jen Tangمشاهده پروفایل

استاد

• Structural Biology
• Biochemistry
• Molecular Biology
• +۴ مورد دیگر

Wei-Jen Tang is a Professor at the University of Chicago, affiliated with the Ben May Department of Cancer Research. His work integrates structural biology and biochemistry to study protein interactions critical to human health, particularly in Alzheimer's disease, diabetes, and bacterial pathogenesis. Education: B.S. in Zoology, National Taiwan University; Ph.D. in Biological Sciences, University of Texas, Austin; Postdoctoral training in Virology and Pharmacology at University of Texas Southwestern. His research focuses on: Amyloid Peptide-Degrading Proteases: IDE and PreP for Alzheimer's and diabetes. Chemokines: CCL5 and CCL3 in inflammation and HIV. Bacterial Toxins: Edema factor in anthrax and bio-defense. Recent publications highlight structural insights into IDE, PreP, and anthrax toxins, with keywords spanning Structural Biology , Biochemistry , and Therapeutics . Funding includes NIH and American Heart Association grants. Awards include AHA Established Investigator and Cancer Research Foundation Young Investigator. Lab updates note new members and a 2025 publication on PreP.

Jacques Archambaultمشاهده پروفایل

استاد

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +۴ مورد دیگر

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

• Cancer Genomics
• Precision Medicine
• Colorectal Cancer Research
• +۵ مورد دیگر

Tobias Sjöblom serves as Professor and Head of Department at Uppsala University's Department of Immunology, Genetics and Pathology, where he leads the Cancer Precision Medicine research program. His work bridges clinical oncology and molecular biology, with particular focus on translating genomic findings into clinical applications for cancer patients. His research interests center on cancer genomics, precision medicine, and molecular diagnostics, with extensive work on colorectal cancer biology and treatment. Sjöblom's laboratory investigates how genetic variations influence cancer development, progression, and response to therapy, particularly focusing on pharmacogenomic biomarkers that can guide personalized treatment decisions. His work spans from basic molecular mechanisms to clinical applications, with strong emphasis on translating research findings into clinical practice. Analyzing his recent publication record reveals a clear trajectory toward precision oncology applications, with increasing focus on liquid biopsy technologies, AI-assisted diagnostics, and biomarker-driven treatment strategies. His research demonstrates a consistent pattern of investigating how specific genetic alterations (particularly in NAT2, CYP2D6, and other metabolic enzymes) can be leveraged for targeted cancer therapies. The interdisciplinary nature of his work is evident in collaborations spanning molecular biology, clinical oncology, bioinformatics, and medical imaging. Sjöblom has established significant research infrastructure through initiatives like the U-CAN biobank, creating valuable resources for cancer research across Sweden. His leadership extends to developing novel methodologies for cancer genomics and diagnostics, including advanced techniques for mutation detection and tissue analysis. His laboratory maintains strong clinical connections, working closely with oncologists and surgeons to ensure research questions address real clinical challenges. This translational approach has resulted in numerous publications in high-impact journals including Nature, Science, and Cell Death and Disease, demonstrating the significance and quality of his contributions to cancer research.

Kunihiko Kanekoمشاهده پروفایل

استاد

• Theoretical Biophysics
• Complex Systems
• Chaos
• +۶ مورد دیگر

Kunihiko Kaneko is a Professor at the Niels Bohr Institute, University of Copenhagen, with a distinguished career in theoretical biophysics and complex systems. He received his PhD and MSc in Physics from the University of Tokyo, and has held leadership roles at the Universal Biology Institute and Center for Complex Systems Biology. PhD Physics, 1984 - University of Tokyo MSc Physics, 1981 - University of Tokyo His research spans five primary areas: Universal Biology, Evolutionary Constraints, Ecosystem Dynamics, Neural Cognition, and Universal Anthropology. He has published extensively on multi-level consistency principles, dimensional reduction in biological systems, and reciprocity between robustness and plasticity across scales. Recent publications show strong focus on microbial ecosystems (2025), evolutionary game theory (2025), neural modular architectures (2024), and dimensional reduction in cellular systems (2024). His work bridges physics and biology through dynamical systems theory applied to diverse phenomena from protocells to human societies.

Jeff S Abramsonمشاهده پروفایل

استاد

• Membrane Transport Proteins
• Structural Biology
• Sugar Transporters
• +۵ مورد دیگر

Jeff S Abramson is a Professor of Physiology in the David Geffen School of Medicine at the University of California Los Angeles (UCLA). His research focuses on the structural and functional characterization of membrane transport proteins, particularly sugar transporters and mitochondrial channels. He maintains an active laboratory investigating the molecular mechanisms of cellular transport processes. Dr. Abramson's primary research interests center on membrane transport proteins, with particular emphasis on sugar symporters and voltage-dependent anion channels (VDACs). His work combines structural biology, biophysics, and biochemistry to understand the molecular mechanisms of transport, including conformational changes during transport cycles, substrate recognition, and regulation by membrane potential. His research has significant implications for understanding metabolic disorders, mitochondrial function, and potential therapeutic targets. Analysis of Dr. Abramson's publication record reveals a consistent focus on membrane protein structure-function relationships over the past two decades. His work demonstrates expertise in X-ray crystallography, cryo-electron microscopy, and functional assays to characterize transport proteins. Recent publications show increasing emphasis on mitochondrial biology, particularly VDAC structure and function, while maintaining his longstanding interest in sugar transport mechanisms. His research bridges fundamental biophysical principles with potential biomedical applications in metabolic diseases. Dr. Abramson has been awarded multiple NIH grants supporting his research, including the R35GM135175 grant titled 'Deciphering molecular details of cellular sugar transport and their roles in disease' (2020-2024), R01GM124783 'Functional and structural studies of unique pathogenic transporters involved in glycobiology' (2017-2021), and R01GM078844 'Structural and functional characterization of sugar transporters in health and disease' (2006-2020). As Principal Investigator, Dr. Abramson has mentored numerous graduate students and postdoctoral researchers. His laboratory has made significant contributions to understanding the structure-function relationships of membrane transport proteins through collaborations with researchers across multiple disciplines. The lab utilizes advanced techniques including X-ray crystallography, cryo-EM, electrophysiology, and computational modeling to address fundamental questions about membrane protein mechanisms. Dr. Abramson's laboratory is part of UCLA's broader research ecosystem focused on structural biology and membrane protein research. His work intersects with several research centers at UCLA including those focused on metabolic diseases and structural biology. The lab maintains active collaborations with researchers specializing in biophysics, computational modeling, and disease mechanisms to translate basic findings into potential biomedical applications.

Prashant Maliمشاهده پروفایل

استاد

• Genome Engineering
• RNA Editing
• Stem Cell Research
• +۴ مورد دیگر

Prashant Mali is a Professor in the Department of Bioengineering at the University of California, San Diego . His research bridges genome engineering, RNA biology, and biomedical applications, with a focus on CRISPR-Cas systems and ADAR-mediated RNA editing. Education : Ph.D. in Bioengineering Key Affiliations : UC San Diego, Altman Clinical and Translational Research Institute Dr. Mali's work centers on CRISPR-Cas9 technology , RNA editing , and human pluripotent stem cells . His lab develops tools for programmable gene regulation, synthetic lethal screens, and metabolic pathway analysis in disease contexts. Recent publications highlight innovations in circular RNA engineering , ADAR activity mapping , and metabolic reprogramming in cancer . His team employs multi-omics approaches and in vivo models to translate genome editing into clinical applications. Students and Collaborators Current Lab Members : Sami Nourreddine (Postdoc), Amir Dailamy (Graduate), Andrew Portell (Graduate), Michael Tong (Graduate) Alumni : Kyle Ford (PhD 2022), Nathan Palmer (PhD 2022), Udit Parekh (PhD 2021) Research Themes CRISPR Screens : Synthetic lethal interactions, oncogenic pathways, metabolic vulnerabilities RNA Editing : ADAR engineering, circular guide RNAs, clinical translation Tissue Engineering : Vascularized organoids, cardiac maturation, ex vivo models

Scott C. Garmanمشاهده پروفایل

استاد

• Structural Biology
• Glycoproteins
• Lysosomal Storage Diseases
• +۲ مورد دیگر

Scott Garman is Professor of Biochemistry at UMass Amherst, focusing on structural biology of glycoproteins in human diseases. PhD from Harvard University. Research areas: Lysosomal enzyme mechanisms in storage diseases (Fabry, Schindler); Malaria surface protein structures; Antibody-receptor interactions. Utilizes X-ray crystallography to study enzyme mutations causing disease. Key findings: Determined structures of α-galactosidase (Fabry disease) and α-NAGAL (Schindler disease), revealing molecular bases for enzyme dysfunction. Developed models for enzyme trafficking and substrate processing. Laboratory: Investigates protein folding diseases and develops therapeutic strategies. Collaborates on malaria vaccine development and antibody engineering.

Albert M. Berghuisمشاهده پروفایل

استاد

• Antibiotic Resistance
• Structural Biology
• X-ray Crystallography
• +۳ مورد دیگر

Albert M. Berghuis is a Professor in the Department of Biochemistry at McGill University's Faculty of Medicine. His research focuses on structural mechanisms of antibiotic resistance and fungal pathogenesis using advanced techniques including X-ray crystallography, electron microscopy, and computational chemistry. His primary research interests include: Structural basis of antibiotic resistance mechanisms, particularly against aminoglycosides Development of novel antimicrobials through structure-based drug design Structural studies of fungal-specific metabolic pathways for antifungal drug discovery Enzyme mechanisms involving protein-small molecule interactions Analysis of his recent publications reveals a consistent focus on structural elucidation of resistance mechanisms, with particular emphasis on aminoglycoside-modifying enzymes and fungal targets. His work bridges structural biology with therapeutic development, showing strong translational potential in combating antimicrobial resistance. Professor Berghuis maintains the Berghuis Lab with facilities in both the McIntyre Medical Sciences Building and the Francesco Bellini Life Sciences Building. His laboratory employs integrated structural biology approaches to tackle pressing problems in infectious disease treatment.

• Bacteriophage Therapy
• Antimicrobial Resistance
• Gut Microbiota
• +۳ مورد دیگر

Dr. Alicia Fajardo Lubian serves as a Research Fellow at the Westmead Clinical School within the University of Sydney's Faculty of Medicine and Health. Her work bridges bacteriophage therapy, antimicrobial resistance, and gut microbiome dynamics, with a focus on translating research into clinical solutions for infectious diseases. Her research explores the interplay between bacteriophages and human immunity, antibiotic effects on microbial communities, and molecular mechanisms of pathogen evolution. She employs genomic and experimental approaches to investigate Klebsiella pneumoniae, Escherichia coli, and phage-based therapeutics. Publications spanning 2014-2025 demonstrate concentrated expertise in antimicrobial resistance surveillance (e.g., AGAR reports), phage-immune interactions, and microbiome disruption models. Over 85% of articles involve international collaborations, reflecting strong engagement with global health challenges. Awards: EMCR Emerging Star Funding (2022) Grant involvement includes the 2022 EMCR Emerging Star Funding from the Faculty of Medicine and Health, supporting innovative research in phage therapeutics.

• Bone Biology
• Skeletal Disorders
• Wnt Signaling Pathways
• +۵ مورد دیگر

Dr. Timur Alexander Yorgan is a prominent researcher at the Department of Osteology and Biomechanics at University Medical Center Hamburg-Eppendorf (UKE). Holding a Dr. rer. nat. degree, he has established himself as a leading figure in bone biology with over 60 publications spanning from 2013 to 2025. His research is deeply integrated with key institutional research areas including the Hamburg Center of Neuroscience and immunology research networks at UKE. Dr. Yorgan's research focuses on skeletal development, bone remodeling, and genetic bone disorders, with particular emphasis on Wnt signaling pathways and their role in bone homeostasis. His work spans multiple approaches from molecular genetics to translational studies, investigating osteoblast and osteocyte biology, genetic mechanisms underlying disorders like osteogenesis imperfecta, and the effects of various mutations on skeletal integrity. Recent research has expanded into the gut-bone axis, mechanobiology of bone cells, and neuro-immune interactions affecting bone metabolism. Analysis of Dr. Yorgan's publication record reveals a consistent trajectory of high-impact research in bone biology. His work increasingly explores interdisciplinary connections between bone metabolism and other physiological systems, with growing emphasis on translational approaches for therapeutic interventions. The research demonstrates sophisticated use of mouse models and molecular techniques to unravel complex bone disorders and identify potential treatment targets. Dr. Yorgan appears to be actively involved in collaborative research across multiple institutions, as evidenced by his extensive publication record with numerous co-authors from various departments and institutions. His work is frequently published in high-impact journals including Journal of Bone and Mineral Research, Nature Communications, and Bone Research. The Department of Osteology and Biomechanics at UKE, where Dr. Yorgan is based, is part of a vibrant research ecosystem that includes the Hamburg Center of Neuroscience and other key research networks focusing on immunology, oncology, and cardiovascular research. This collaborative environment enables interdisciplinary approaches to understanding skeletal disorders and developing novel therapeutic strategies.

Kyu Y. Rheeمشاهده پروفایل

استاد

• Tuberculosis
• Antibiotic Resistance
• Metabolomics
• +۳ مورد دیگر

Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.